IDXX stock sentiment todayIDEXX Laboratories, Inc.

A high-quality diagnostic monopoly facing temporary macro headwinds and valuation compression, waiting for a clear vet-visit recovery.

Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for IDXX. Not financial advice.

The narrative is currently dominated by a post-earnings hangover and concerns over declining clinic visit volumes. While long-term sentiment remains structurally positive due to the 'humanization of pets' trend, short-term chatter focuses on whether the stock can bounce back from its 16% annual slump and the impact of recent executive appearances on investor confidence.

• ·Softness in companion animal clinical visits
• ·Post-earnings momentum loss
• ·Speculation on a 2026-2027 recovery cycle
• ·Resilience of recurring diagnostic revenue

IDEXX maintains an elite financial profile with high ROIC (20%+) and a business model where 80% of revenue is recurring. However, its valuation remains 'rich' on a P/E basis (approx. 45-50x) compared to historical growth rates that have decelerated from pandemic peaks.

• ·Operating margins consistently above 30%
• ·Double-digit organic revenue growth in cloud software
• ·Low debt-to-equity ratio
• ·High free cash flow conversion

Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.

Strong conviction — insiders and patient capital are backing this.

• ·No open-market insider trades in the last 120 days.

Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.

• ·Discretionary spending pressure on pet owners leading to deferred testing
• ·Increasing competition from point-of-care disruptors
• ·Multiple compression if double-digit EPS growth doesn't materialize
• ·Foreign exchange volatility impacting international segments

How direct competitors stack up against IDXX right now.

• HOT
  ZTSZoetis Inc.

  HOTTER — offers a more diversified pharmaceutical portfolio with stronger recent price momentum and less sensitivity to diagnostic-specific visit declines.

  See full analysis →
• COLD
  ELANElanco Animal Health

  COLDER — struggling with significantly higher leverage and lower margins despite a more attractive absolute valuation.

  See full analysis →
• NEUTRAL
  HSICHenry Schein, Inc.

  NEUTRAL — trading at a much lower P/E, but lacks the high-margin proprietary technology moat that justifies IDEXX's premium.

  See full analysis →

Consensus average of 7 analysts · median 675.00

Source: StockAnalysis.com · updated 2026-08-14

• TIKR.com
  Down 16% in the Last 12 Months, Can IDEXX Stock Bounce Back in 2027?
• Stocktwits
  IDXX: Idexx Laboratories Inc Latest Stock Price, Analysis, News and Trading Ideas
• Yahoo Finance
  Idexx (IDXX) Down 7.8% Since Last Earnings Report: Can It Rebound?
• TradingView
  IDXX Stock Price and Chart — NASDAQ:IDXX
• Moomoo
  IDXX 260918 560.00P (IDXX260918P560000) Stock Options Chain | Quotes & News
• Quiver Quantitative
  Why IDEXX Laboratories (IDXX) Stock Is Down Today